CD2 and type 1 diabetes mellitus: Another approach is to combine these Treg expanding therapies with agents that modulate effector T cell function, such as monoclonal antibodies targeting CD3 on T cells [15,74,75,76,77], CD2 on T cells [78,79], antithymocyte globulin [80,81], or potentially a small molecule inhibitor of effector T cells activated by the T1D-risk HLA-DQ8 molecule in T1D [82,83,84].